- 05/01/2019
- EISAI BUYS OUT PURDUE RIGHTS TO END COLLABORATION
- 04/24/2019
- EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AND PERAMPANEL AT ANNUAL AMERICAN ACADEMY OF NEUROLOGY MEETING
- 03/29/2019
- DATA SAFETY MONITORING BOARD RECOMMENDS CONTINUATION OF PHASE III CLINICAL STUDIES OF BACE INHIBITOR ELENBECESTAT IN EARLY ALZHEIMER’S DISEASE
- 03/22/2019
- INITIATION OF PHASE III CLINICAL TRIAL OF BAN2401 IN EARLY ALZHEIMER’S DISEASE
- 03/12/2019
- Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
- 02/13/2019
- EISAI SUBMITS APPLICATION IN EUROPE SEEKING APPROVAL FOR FYCOMPA® AS TREATMENT FOR PEDIATRIC PATIENTS WITH EPILEPSY
- 02/04/2019
- Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study at the Sleep Research Society’s Conference: Advances in Sleep and Circadian Science
- 01/30/2019
- SUPPLEMENTARY NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR FYCOMPA® AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES, AS WELL AS NEW FORMULATION
- 01/22/2019
- EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE FOURTH TIME
- 01/12/2019
- 2019 Lenvatinib Launching Ceremony Jointly Held by Eisai China and MSD China
